Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT03765333
Recruiting Observational

GETNE Registration of Thyroid Cancer

NCT03765333 · tracked via the Priya Life Science Spain tracker
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Phase
Observational
Started
2019-05-28
Last updated
2026-09-22

Condition(s) studied

Thyroid Cancer

Study summary

An epidemiological, observational, multicenter, cross-sectional, retrospective study on patients ≥ 18 years visited in the oncology services of the participating centers with diagnosis of primary thyroid cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients older than 18 years with diagnosis of differentiated, medullary or anaplastic thyroid cancer confirmed by histopathology. * Patients who agree to participate and are able to understand the information sheet and sign the informed consent Exclusion Criteria: * Patients under 18 years of age. * Patients with other types of thyroid cancer or whose histopathological diagnosis has not been confirmed. * Patients who do not have the relevant basic information to be included in the study, according to the criteria of the principal investigator.

Primary outcome measure(s)

  • Hystopathological characteristics of the tumor — Baseline
    Based on pathologist evaluation of biopsy including differentiated, medullar or anaplasic.
  • Situation of the tumor at first-diagnosis — Baseline
    Local tumor, locoregional tumor or metastatic disease.
  • Tumor-Node-Metastasis classification — Baseline
    Based on the AJCC (American Joint Committee on Cancer) 2018 TNM system: T for extent or size of the tumor, N for lymph nodes spread and M for metastasis.
  • Tumor Stage — Baseline
    From I to IV, based on the interpretation of the TNM classification and depending on the hystopathological characteristics of the tumor.

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitari Vall d'Hebron Barcelona Barcelona Recruiting

More Grupo Espanol de Tumores Neuroendocrinos trials in Spain

Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors Recruiting
Sacituzumab govitEcan in THYroid Cancers Recruiting
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus. Recruiting

Other trials for the same condition

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03765333 on ClinicalTrials.gov ↗ ← All trials in Spain